BSECompany UpdateResults1d ago
Kabra Drugs Ltd
Newspaper Advertisement for the quarter ended 30-September-2026
Kabra Drugs Ltd has published unaudited financial results for the quarter ended 30th September 2026 in a newspaper advertisement, as per Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
BSECompany UpdateRegulatory6 Nov 2026
Kabra Drugs Ltd
Undertaking for Non-Applicability of Regulation 32 of SEBI (LODR)
Kabra Drugs Ltd, formerly known as Aanjaay Industries Ltd, has submitted an undertaking to BSE stating that Regulation 32 of SEBI (LODR) Regulations, 2015 is not applicable for the quarter ended on 30th September 2026 as the company has not issued any shares through public issue, rights issue, or preferential issue.
BSEBoard MeetingResults30 Oct 2026
Kabra Drugs Ltd
Kabra Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2026 ,inter alia, to consider and approve Intimation of Board Meeting to be held on 06th November 2026
Kabra Drugs Ltd has scheduled a Board Meeting on 06/11/2026 to consider and approve unaudited financial results for the quarter ended 30/09/2026.
BSECompany UpdateRegulatory12 Oct 2026
Kabra Drugs Ltd
Certificate pursuant to Regulation 74 (5) of SEBI regulation, 2018.
Kabra Drugs Ltd has submitted a certificate confirming compliance with Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 30th September 2026.
BSEAGM/EGM1 Oct 2026
Kabra Drugs Ltd
Scrutinizers Report
Kabra Drugs Ltd has submitted the voting results of its 37th Annual General Meeting, held on September 30, 2026, as per SEBI regulations.
BSEAGM/EGMMgmt Change30 Sept 2026
Kabra Drugs Ltd
Proceedings of Annual General Meeting
Kabra Drugs Ltd (formerly known as Aanjaay Industries Ltd) held its 37th Annual General Meeting on September 30, 2026, where the company adopted audited financial statements and re-appointed Mr. Kuniamuthur Nanjappan Anand as a director. The company also appointed Ms. Moonam Kapoor and Mrs. Twinkle Agarwal as additional non-executive independent directors and company secretary, respectively. The voting results will be announced within 48 hours and posted on the company's website.
BSEInsider Trading / SAST28 Sept 2026
Kabra Drugs Ltd
Closure of Trading Window
Kabra Drugs Ltd has announced the closure of its trading window for all designated persons and their immediate relatives from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter ended September 30, 2026.
BSEGeneralResults8 Sept 2026
Kabra Drugs Ltd
Reg. 34 (1) of Annual Report for the financial year 2025-2026
Kabra Drugs Ltd, now known as Aanjaay Industries Ltd, has submitted its annual report for the financial year 2025-2026, along with a notice for its 37th Annual General Meeting on September 30, 2026. The report includes changes in the board of directors and key managerial personnel, as well as the appointment of a new non-executive independent director and secretarial auditor.
BSECorp. ActionResults3 Sept 2026
Kabra Drugs Ltd
Book Closure and schedule of events for E-voting
Kabra Drugs Ltd has announced book closure and e-voting schedule for its upcoming Annual General Meeting (AGM) to be held on September 30, 2026.
BSECompany UpdateMgmt Change2 Sept 2026
Kabra Drugs Ltd
Appointment of Internal Auditor of the Company
Kabra Drugs Ltd has appointed M/s Karthik L & Associates as its Internal Auditor for the Financial Year 2026-2027, in compliance with the Companies Act, 2013 and SEBI (LODR) Regulations, 2015.
BSECompany UpdateMgmt Change2 Sept 2026
Kabra Drugs Ltd
Appointment of Secretarial Auditor of the Company
Kabra Drugs Ltd has appointed Mrs. Twinkle Agarwal as its Secretarial Auditor for the financial year 2026–2027 to 2027–2031, in compliance with the Companies Act, 2013 and SEBI (LODR) Regulations, 2015.
BSEBoard MeetingResults2 Sept 2026
Kabra Drugs Ltd
Outcome of Board Meeting held on 02nd September 2026
The Board of Directors of Kabra Drugs Ltd held a meeting on September 2, 2026, and considered and approved various items, including the Director's Report and Corporate Governance Report for the financial year ended March 31, 2026. The company also announced the re-appointment of Mr. Kuniamuthur Nanjappan Anand as Director, the appointment of M/s Karthik L & Associates as Internal Auditors, and the appointment of Ms. Moonam Kapoor and Mrs. Twinkle Agarwal as Directors and Secretarial Auditor, respectively. The meeting also approved the Notice of the 37th Annual General Meeting, which will be held on September 30, 2026.
BSECompany Update29 Aug 2026
Kabra Drugs Ltd
Intimation regarding change in resgistered Office of the Company
Kabra Drugs Ltd has changed its registered office address from Indore to Chennai, as per the order of the Regional Director and Registrar of Companies. The change is effective from August 28, 2026.
BSEBoard MeetingMgmt Change27 Aug 2026
Kabra Drugs Ltd
Kabra Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/09/2026 ,inter alia, to consider and approve Intimation of Board Meeting to ....
Kabra Drugs Ltd has informed BSE that a meeting of the Board of Directors is scheduled on 02/09/2026 to consider and approve various business, including Director's Report, closure of Register of Members, and appointment of Directors and Auditors.
BSECompany UpdateMgmt Change18 Aug 2026
Kabra Drugs Ltd
Reconstitution of the Composition of the Board & Committees of Regulation 30 of SEBI (LODR) Regulations, 2015
Kabra Drugs Ltd has reconstituted its Board of Directors and Committees as per Regulation 30 of SEBI (LODR) Regulations, 2015, effective from August 12, 2026. The new composition includes Nanjappan Aravind as Executive Director, Managing Director, and Chairperson, and four independent directors: Nikita Sinha, Ritu Tiwari, Moonam Kapoor, and Kuniamuthur Nanjappan Anand.
BSECompany UpdateResults18 Aug 2026
Kabra Drugs Ltd
Newspaper Advertisement for the quarter ended on 30th June 2026.
Kabra Drugs Ltd has published an unaudited financial results for the quarter ended on 30th June 2026 in a newspaper advertisement.
BSECompany UpdateMgmt Change12 Aug 2026
Kabra Drugs Ltd
Resignation of director of Ms. Anand Anitha
Kabra Drugs Ltd announced the resignation of Ms. Anand Anitha as Director of the Company, effective August 12, 2026, citing personal reasons.
BSECompany UpdateRegulatory12 Aug 2026
Kabra Drugs Ltd
Undertaking for Non-Applicability of Reg 32
Kabra Drugs Ltd, now known as Aanjaay Industries Ltd, has submitted an undertaking to the BSE stating that Regulation 32 of SEBI (LODR) Regulations, 2015 is not applicable to the company for the quarter ended 30th June 2026. The company has not issued any shares through public issue, rights issue, or preferential issue during this period.
BSEResultResults12 Aug 2026
Kabra Drugs Ltd
Financials results
Kabra Drugs Ltd (formerly known as Kabra Drugs Limited) has announced its unaudited standalone financial results for the quarter ended June 30, 2026. The company reported a net profit of ₹212.30 lakhs, with revenue from operations at ₹4621.68 lakhs and total income at ₹4629.33 lakhs.
BSEBoard MeetingResults12 Aug 2026
Kabra Drugs Ltd
Outcome of Board Meeting held on 12th August 2026
Kabra Drugs Ltd (formerly known as Kabra Drugs Limited) has announced its unaudited standalone financial results for the quarter ended June 30, 2026. The company reported a net profit of ₹212.30 lakhs, with earnings per share (EPS) of ₹0.90. The results were reviewed by the Audit Committee and approved by the Board of Directors on August 12th, 2026.